RxDoctor Payments Data

Lyndon Lee, MD

Ophthalmology · West Hartford, CTNPI 1114107562

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.9% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 29.1% of the total. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,784in general payments, 2019–2025

Across 281 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sun Pharmaceutical Industries Inc.$777
  • Novartis$662
  • Oyster Point Pharma, Inc.$645
  • Bausch & Lomb Americas Inc.$557
  • Tarsus Pharmaceuticals, Inc.$427
  • plus $2K from 18 others

What the payments were for

  • Grants$5007%
  • Food & beverage$6,16691%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,784 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$171,816
Medicare patients
435
Services billed
2,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner68$130,682
RestasisCyclosporine86$113,382
XiidraLifitegrast78$106,303
MieboPerfluorohexyloctane/Pf112$94,401
CequaCyclosporine63$55,750
LumiganBimatoprost62$44,231
RocklatanNetarsudil Mesylat/Latanoprost33$24,235
CombiganBrimonidine Tartrate/Timolol31$20,191
RhopressaNetarsudil Mesylate34$16,855
TyrvayaVarenicline Tartrate23$14,377
VevyeCyclosporine16$13,875
Cyclosporine35$13,025
Loteprednol Etabonate46$8,661
EysuvisLoteprednol Etabonate15$7,579
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$7,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$557$200,704190 claims
AbbVieRestasis, Lumigan, Combigan$1,976$177,804179 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$427$130,68268 claims
Sun Pharmaceutical Industries Inc.Cequa$777$55,75063 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$289$41,09067 claims
Oyster Point Pharma, Inc.Tyrvaya$645$14,37723 claims
Harrow Eye, LLCVevye$61$13,87516 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$151$8,66146 claims
Kala Pharmaceuticals, Inc.Eysuvis$311$7,57915 claims
Eyevance Pharmaceuticals LLCFlarex$66$3,63926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in West Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →